THE AIRSPEED EQUITY TEAM
- Alexander Nawrocki, PhD
- David Kramer
- Bill Vassilakis
- Dr. Lisa Williams
- Gary Gil
- George Komar
- Gerald “Rocky” McMurray
- Honorable Milton L. Lohr
- Jerry Schneider
- John Meyers
- Khai Minh Pham, MD, PhD
- Kris Skrinak
- Krzysztof Appelt
- Leonard S. Johnson “LS”
- Livia J. Szabó Klimovitsky
- Marek Winiarz, P.E.
- Paul R. Zalucky
- Sebastien R. Goulet
- Tom Gallanis
- Vladymir Rogov
- Walt Czerminski
- ZB Pietrzkowski, PhD
Krzysztof Appelt
Director
Dr. Appelt is a seasoned bio-technology scientist and executive with over 28 years of management experience in the biopharmaceutical industry. He has had extensive experience in the discovery and development of antiviral, antibacterial and anticancer chemotherapeutic agents. Dr. Appelt lead a multidisciplinary team at Agouron Pharmaceuticals which discovered and developed ViraceptTM – an innovative AIDS therapy, and several other compounds discovered using structure-based approached pioneered by Agouron. After Agouron’s acquisition by Warner-Lambert and subsequent merger with Pfizer, Dr. Appelt served as Global Head of Ophthalmology in both organizations.
From 2001 to 2005 Dr. Appelt served as Executive Vice President and Chief Technology Officer at Quorex Therapeutics, a company focused on the discovery of antibacterial and antibiofilm agents. In 2006 Dr. Appelt founded Great Lakes Pharmaceuticals, Inc. and as the President and CEO led the discovery and development of therapeutics to prevent and treat blood infections associated with central venous catheters.
Dr. Appelt received his undergraduate degree in Physiology from Poznan University in Poland and his Ph.D. in Biophysics from the Max Planck Institute in West Berlin. Before joining Agouron Pharmaceuticals in 1987 he was Assistant Professor in Chemistry Department in University of California in San Diego. Dr. Appelt is a co-author of 57 peer reviewed publications, co-inventor of several patents and was awarded several multimillion federal R&D grants.